DAR No 6: Umeclidinium bromide/Vilanterol. Anoro® for COPD

Content tools

Share it

No additions to efficacy, just to price

Umeclidinium/vilanterol is a combination of a muscarinic antagonist and a long acting b2 adrenergic agonist.
No reduction in the risk of exacerbations has been shown.
It does not improve clinical results compared to tiotropium.
The role and contribution of vilanterol to the combination is not clear.
There are no comparative data available with respect to other LAMA+LABA combinations.
Its cardiovascular safety profile is still a concern.

Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

First name, middle initial and last name *

Email *

Current position or occupation *

Place of work *

Suggestions/Comments *